Prof. Dr. Martin Schuler

Research interests: 
  • Molecular mechanisms of drug resistance in cancer treatments
  • Molecular pathognese of lung cancer
  • Mechanisms of immune resistance
  • Drug discovery in cancer treatment
Selected publications: 


Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013 Aug;81(2):155-61.

Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol. 2013 Jul 1. [Epub ahead of print]

Molzan M, Kasper S, Röglin L, Skwarczynska M, Sassa T, Inoue T, Breitenbuecher F, Ohkanda J, Kato N, Schuler M, Ottmann C. Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers. ACS Chem Biol. 2013 Jul 5.

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol. 2013 Jul 1.

Schuler M. [Medical care of the cancer patient - Is it really so different?]. Z Evid Fortbild Qual Gesundhwes. 2013;107(2):116-9.

Hoiczyk M, Grabellus F, Podleska L, Ahrens M, Schwindenhammer B, Taeger G, Pöttgen C, Schuler M, Bauer S. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age. Int J Oncol. 2013 Jul;43(1):23-8.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S. DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors. Cancer Res. 2013 Jun 15;73(12):3661-3670.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013 Jan;8(1):19-30.

Juntermanns B, Sotiropoulos GC, Radunz S, Reis H, Heuer M, Baba HA, Canbay A, Schuler M, Gerken G, Paul A, Kaiser GM. Comparison of the sixth and the seventh editions of the UICC classification for perihilar cholangiocarcinoma. Ann Surg Oncol. 2013 Jan;20(1):277-84.


Welter S, Grabellus F, Bauer S, Schuler M, Eberhardt W, Tötsch M, Stamatis G. Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology. Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):612-7.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2012 Sep;7(9):1440-8.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59.

Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, Fletcher JA, Bauer S. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One. 2012;7(5):e37776.

Meiler J, Guyot M, Hoffarth S, Wesarg E, Höhn Y, Breitenbuecher F, Schuler M. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2012 Aug;138(8):1385-94.

Hoiczyk M, Iliodromitis K, Bauer S, Konorza T, Philipp S, Bankfalvi A, Gerl JM, Schuler M, Erbel R. Intimal sarcoma of the pulmonary artery with unusual findings: a case report. Clin Res Cardiol. 2012 May;101(5):397-401.

Christoph DC, Hoffmann AC, Gauler TC, Asuncion BR, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhard WE, Hirsch FR. Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol. 2012 Apr;7(4):766-7.

Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, Breitenbuecher F. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. J Cancer Res Clin Oncol. 2012 Apr;138(4):545-54.

Broggini N, Tosatti S, Ferguson SJ, Schuler M, Textor M, Bornstein MM, Bosshardt DD, Buser D. Evaluation of chemically modified SLA implants (modSLA) biofunctionalized with integrin (RGD)- and heparin (KRSR)-binding peptides. J Biomed Mater Res A. 2012 Mar;100(3):703-11.

Research group: 
Medical Faculty
Centre for Medical Biotechnology (ZMB)
West German Cancer Center (WTZ)
University Hospital Essen